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FRANKLIN PIERCE LAW CENTER 13
PIERCE LAW PARTICIPATES IN PANDEMIC 
INFLUENZA VACCINE IP MANAGEMENT MEETING 
B Y  S T A N L E Y  K O W A L S K I  ( J D  ’ 0 5 )
O    N APRIL 18, 2006 several members     of the greater PierceLaw community     participated in an important 
meeting held at the World Intellectual 
Property Organization (WIPO) in Geneva, 
Switzerland. Organized by The Centre for 
the Management of Intellectual Property 
in Health Research and Development 
(MIHR <www.mihr.org>), the meeting 
“Intellectual Property Management 
Strategies to Facilitate Early Access and 
Global Health Beneﬁts: Case Studies in 
Pandemic Inﬂuenza and Malaria” had the 
objective of exploring and discussing IP 
issues which impact the distribution of 
vaccines to developing countries, a topic of 
heightened worldwide importance given 
the potential threat of a global inﬂuenza 
pandemic. In an intensive one-day session, 
the diverse panel of world experts worked 
together to formulate a list of realistic, 
creative and dynamic IP management 
options for providing the poor of the 
developing world with access to critically 
essential vaccines. 
The participation of the PierceLaw 
community in this meeting is consonant 
with the mission of the Germeshausen 
Center (GC) as the umbrella organization 
for IP policy analysis, both in principle and 
in practice; that is, it underscores the GC’s 
enduring commitment to tackling challenging 
issues in international IP. By examining the 
broader international context, and also 
engaging in discussions relating to innovative 
IP management strategies for technology 
transfer to and utilization in developing 
countries, the GC seeks to make comprehensive 
and substantive contributions to such 
ongoing collaborative endeavors, from 
policy to strategy to implementation. 
PierceLaw participation is also consistent 
with the establishment of the International 
Development Intellectual Property Clinical 
Program (ID/IP Clinic). Linkages forged between the ID/IP Clinic and international initiatives such as MIHR will synergistically 
advance IP awareness and capacity building in developing countries, for the express purpose of improving public 
health and nutrition. Facilitating the availability of a pandemic inﬂuenza vaccine is just one (very important) 
example of how formulating innovative IP management strategies (and licensing options) can serve the greater global 
public interest. 
Stanley Kowalski (JD ’05) BS in Biology, University of Pittsburgh, Ph.D. in Plant Breeding, Cornell University 
will be supervisor of the Pierce Law ID/IP Clinic.
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